Half of the patients who received a single cilta-cel infusion in early-line relapsed or refractory multiple myeloma were still alive and progression-free five years later, with no additional treatment. That figure comes from the initial 20-patient subgroup of cohort A in the Phase 2 CARTITUDE-2 study, and it matters because five-year treatment-free remission in myeloma, a disease defined by relapse, has not been a realistic expectation from any single intervention.
The weight of that number depends on context. These were early-line relapsed or refractory patients, not the heavily pretreated population cilta-cel was originally developed for. FDA expanded CARVYKTI’s approval in April 2024 to adults with at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent, so the regulatory path for this population already exists. CARTITUDE-2 is now giving that label a five-year durability argument it did not have before.
The trial design itself adds a wrinkle worth tracking. CARTITUDE-2 is a multi-cohort, single-arm Phase 2 study, not a randomized trial, and cohort A started with just 20 patients. Single-arm data at small N can produce striking response rates that soften at scale. What CARTITUDE-2 does offer that randomized trials cannot, at least not yet, is sheer follow-up time: five years of progression-free survival in patients who received one infusion and then stopped treatment is a durability signal that accumulated trial experience in this class has not consistently delivered. For comparison, CARTITUDE-2’s design spans multiple cohorts, each addressing a different clinical setting, so the long-term cohort A data sits alongside an evolving evidence base rather than standing alone.
The practical implication for trial teams is that durability data at five years shifts the conversation from response depth to treatment independence, a meaningful distinction for myeloma patients who currently cycle through maintenance regimens indefinitely. If larger randomized data from the CARTITUDE program corroborates this durability rate, the case for moving CAR-T earlier in the treatment sequence becomes harder to dismiss on clinical grounds. The number to watch is whether the treatment-free survival fraction holds as cohorts with more patients reach comparable follow-up.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
